

[137] PRECISE BIO BIO-MANUFACTURING

Aryeh Batt¹, Lior Shav¹, ¹ Precise Bio

Investment Rational

Precise Bio has developed a proprietary, laser based, 4D bio-printing technology allowing to bio-manufacture organs and tissues on a cell-to-cell resolution while maintaining structural integrity and cell viability. The technology allows printing functional tissues and organs targeting different indications, including as an alternative to organ donations. In ophthalmology, the company is the first to have ever transplanted a cell based printed cornea graft into animals. The company's founders are Dr. Anthony Atala and Prof. Shay Soker from WFIRM and Aryeh Batt.

Business Strategy

The company is pursuing partnerships and collaboration in different fields, aiming to leverage its expertise in bio manufacturing with each partner's core competencies.

Core Technology

Precise Laser based printing technology is the most accurate printing technology available today. Combining our printing technology with advanced molecular and cell biology, bio materials, unique bio-ink and multi-disciplinary engineering capabilities allows the company to target more complex tissues and a broad spectrum of indications.

Product Profile/Pipeline

In ophthalmology – the company's first product is a corneal graft (DSEK). The company has been the first to have ever transplanted and 3D printed graft for EK in animals and is on track for human studies in 2019. The company collaborates with US eye banks.

In addition, the company's pipeline includes various other ophthalmic indications, some pursued internally and other are already worked on in collaboration with biopharma/strategic companies.

What's Next?

On the cornea program, the company is running additional pre-clinical studies and is in preparation for its FIH studies including transition to relevant GLP/GMP requirements. The company is in the process of reviewing additional programs (both internal and as collaborative projects with multinational players).